Evidence map›Paper›PMID 38776019›Full record

ArticleClinical and experimental medicine2024

The clinical significance of TAT, PIC, TM, and t-PAIC in vascular events of BCR/ABL-negative myeloproliferative neoplasms.

Kangle Huang, Qiuyu Mo, Chushu Liao, Shan Feng, Guanghua Liu, Duanfeng Jiang, Ping Lei

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kangle HuangDepartment of Hematology, The Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Jiefang West Road, No. 61, Changsha, 410005, China.
Qiuyu MoDepartment of Oncology, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, 545007, Guangxi, China.
Chushu LiaoDepartment of Hematology, The Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Jiefang West Road, No. 61, Changsha, 410005, China.
Shan FengDepartment of Hematology, The Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Jiefang West Road, No. 61, Changsha, 410005, China.
Guanghua LiuDepartment of Hematology, The Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Jiefang West Road, No. 61, Changsha, 410005, China.
Duanfeng JiangDepartment of Hematology, The Fourth Affiliated Hospital of Guangxi Medical University, Heping Road, No. 156, Liuzhou, 545007, Guangxi, China. duanfeng989949@126.com.
Ping LeiDepartment of Hematology, The Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Jiefang West Road, No. 61, Changsha, 410005, China. 2506421372@qq.com.

Funding

Hainan Provincial Health Industry Research Project 22A200261Hainan Provincial Health Industry Research Project 22A200263Hunan Provincial Natural Science Foundation Joint Fund Project 2024JJ9142
6 · The paper itself

Abstract

Predicting the likelihood vascular events in patients with BCR/ABL1-negative myeloproliferative neoplasms (MPN) is essential for the treatment of the disease. However, effective assessment methods are lacking. Thrombin-antithrombin complex (TAT), plasmin-α

Indexed as

Fusion Proteins, bcr-ablMyeloproliferative DisordersAdultAgedAged, 80 and overalpha-2-AntiplasminAntithrombin IIIBiomarkersClinical RelevanceFemaleFibrinolysinHemorrhageHumansMaleMiddle AgedPeptide Hydrolasesalpha-2-AntiplasminAntithrombin IIIantithrombin III-protease complexBiomarkersFibrinolysinFusion Proteins, bcr-ablPeptide Hydrolasesplasmin-plasmin inhibitor complexThrombomodulinHemorrhagic eventsMyeloproliferative neoplasmsPlasmin-α2-plasmininhibitor complex (PIC)Thrombin-antithrombin complex (TAT)Thrombomodulin (TM)Thrombotic eventsTissue plasminogen activator-inhibitor complex (t-PAIC)

Identifiers

PMID38776019
PMCPMC11111525

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.